RxDoctor Payments Data

Louis May, MD

Gastroenterology · New City, NYNPI 1164426987

Payments from drug & device makers

$2,877in general payments, 2019–2025

Across 146 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$874
  • Gilead$789
  • Johnson & Johnson$328
  • Pfizer$206
  • QOL Medical, LLC$143
  • Bristol Myers Squibb$99
  • plus $438 from 11 others

What the payments were for

  • Speaking & faculty fees$201%
  • Grants$201%
  • Food & beverage$2,80698%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,877 in reported general payments places this provider in the 55th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$242,003
Medicare patients
611
Services billed
1,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$81,261
Mesalamine29$45,390
LinzessLinaclotide34$28,238
MotegrityPrucalopride Succinate12$14,229
ClenpiqSod Picosulf/Mag Ox/Citric Ac46$7,658
Famotidine485$5,947
Omeprazole358$3,956
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates55$3,272
Ursodiol19$2,753
Pantoprazole Sodium112$1,625
SuprepSodium, Potassium,mag Sulfates12$1,365
Esomeprazole Magnesium20$1,135
Hydrocortisone11$929
Lansoprazole22$571
Rabeprazole Sodium19$508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$874$28,23834 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$45$14,22912 claims
Ferring Pharmaceuticals Inc.Clenpiq$98$7,65846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →